165 related articles for article (PubMed ID: 16207150)
1. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.
Liu CH; Peck K; Huang JD; Lin MS; Wang CH; Hsu WP; Wang HW; Lee HL; Lai ML
Pharmacogenomics; 2005 Oct; 6(7):731-47. PubMed ID: 16207150
[TBL] [Abstract][Full Text] [Related]
2. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.
Du J; Xing Q; Xu L; Xu M; Shu A; Shi Y; Yu L; Zhang A; Wang L; Wang H; Li X; Feng G; He L
Pharmacogenomics; 2006 Sep; 7(6):831-41. PubMed ID: 16981844
[TBL] [Abstract][Full Text] [Related]
3. Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray.
Wen S; Wang H; Ding Y; Liang H; Wang S
Genet Test; 2004; 8(4):411-6. PubMed ID: 15684873
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
6. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
Lee SJ; Goldstein JA
Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.
Li D; Zhang GL; Lou YQ; Li Q; Wang X; Bu XY
J Clin Pharm Ther; 2007 Feb; 32(1):89-95. PubMed ID: 17286792
[TBL] [Abstract][Full Text] [Related]
8. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population.
Shi Y; Xiang P; Li L; Shen M
Forensic Sci Int; 2011 Apr; 207(1-3):183-7. PubMed ID: 21071160
[TBL] [Abstract][Full Text] [Related]
9. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population.
Park SY; Kang YS; Jeong MS; Yoon HK; Han KO
J Clin Pharm Ther; 2008 Feb; 33(1):61-5. PubMed ID: 18211618
[TBL] [Abstract][Full Text] [Related]
10. Novel mutations of CYP3A4 in Chinese.
Hsieh KP; Lin YY; Cheng CL; Lai ML; Lin MS; Siest JP; Huang JD
Drug Metab Dispos; 2001 Mar; 29(3):268-73. PubMed ID: 11181494
[TBL] [Abstract][Full Text] [Related]
11. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
[TBL] [Abstract][Full Text] [Related]
12. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH; Lin CT; Wu YJ; Wu LS
J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
[TBL] [Abstract][Full Text] [Related]
13. Allele and genotype frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 gene polymorphisms among mainland Tibetan, Mongolian, Uyghur, and Han Chinese populations.
Qi G; Han C; Zhou Y; Wang X
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):219-227. PubMed ID: 34689350
[TBL] [Abstract][Full Text] [Related]
14. Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population.
Hu GX; Dai DP; Wang H; Huang XX; Zhou XY; Cai J; Chen H; Cai JP
Pharmacogenomics; 2017 Mar; 18(4):369-379. PubMed ID: 28244811
[TBL] [Abstract][Full Text] [Related]
15. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
16. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
17. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
[TBL] [Abstract][Full Text] [Related]
18. A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population.
Du J; Xu Y; Duan S; Zhang A; Xuan J; Wang L; Yu L; Wang H; Li X; Feng G; He L; Xing Q
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1200-4. PubMed ID: 19591893
[TBL] [Abstract][Full Text] [Related]
19. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
